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Conclusions An overnight fasting period and a concomi-
tantly stressful condition induce inappropriate 3BOHB 
increase in T2DM. Point-of-care capillary 3BOHB may be 
useful before any procedural/surgical intervention in these 
patients.
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Introduction
Ketone bodies (KB), acetoacetate (AcAc) and 3-hydroxy-
butyrate (3BOHB), are metabolites produced by free fatty 
acid (FFA) beta-oxidation, and utilized by peripheral cells 
as an energy source [1, 2]. Ketogenesis is stimulated when 
circulating FFA is increased from lipolysis, such as during 
either prolonged fasting or adrenergic activation [3].
Although blood KB concentrations in healthy individu-
als are low, they can increase 100 folds during diabetic 
ketoacidosis [4]. Recently, there has been a resurgent inter-
est about these substrates, since ketoacidosis may be a rare 
complication of sodium-glucose co-transporter 2 (SGLT2) 
inhibitors [5]; moreover, it was shown that 3BOHB is an 
endogenous inhibitor of histone deacetylases (HDACs) and 
its metabolites, acetyl-CoA and succinyl-CoA, have them-
selves signalling activities [6].
Several years ago Lommi and colleagues reported 
increased concentration of KB in chronic heart failure 
(CHF), in proportion to the severity of cardiac dysfunc-
tion and neurohormonal activation [7]. In a subsequent 
study, the same authors suggested that severe CHF is a 
ketosis-prone state determined by augmented supply 
of FFA, induced by increased stress hormone-related 
lipolysis [8]: after 20 h of fasting, the reported total KB 
Abstract 
Purpose Ketone bodies, 3-hydroxybutyrate (3BOHB), 
and acetoacetate derive from increased free fatty acid beta-
oxidation, thus reflecting marked insulin deprivation with 
or without decompensated diabetes. Objectives of this 
study were (1) to determine circulating levels of 3BOHB 
in patients with and without type 2 diabetes (T2DM), 
before and after an elective coronary angiography; (2) to 
detect 3BOHB modification during the procedure; (3) to 
study possible associations between 3BOHB and clinical 
parameters/outcomes.
Methods Sixteen T2DM (72 ± 11 years) and 22 matched 
controls (71 ± 12 years) undergoing elective coronary angi-
ography were enrolled. In all subjects, biohumoral param-
eters were determined at hospital admission. Point-of-care 
determinations of 3BOHB, glucose, and creatinine were 
performed, at 7 a.m, immediately before and after the pro-
cedure. The duration of the fasting period and of the proce-
dure was recorded.
Results T2DM had significantly higher fasting 
(0.538 ± 0.320 vs 0.255 ± 0.197  mM/l;   p = 0.005) and 
pre-procedural (0.725 ± 0.429 vs 0.314 ± 0.205; p = 0.002) 
3BOHB concentrations than controls. Similarly, absolute 
increment of 3BOHB from the morning value was signifi-
cantly greater in T2DM (0.369 ± 0.252 vs 0.127 ± 0.135 in 
controls; p = 0.002). Significant correlations were observed 
between pre-procedure 3BOHB and glucose levels 
(r = 0.586; p < 0.0001) and between pre-procedure 3BOHB 
and fasting creatinine concentrations (r = 0.364; p = 0.029).
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concentrations in patients with CHF were 600 µmol/l as 
compared to 350  µmol/l in controls. On the other hand, 
KB production can also represent an efficient energy sub-
strate for the heart, providing more cellular energy per 
unit of oxygen consumed than glucose or FFA [9]. Myo-
cardial KB metabolism maintains cardiac protein acety-
lation and ROS homeostasis, in the injured heart [10]. 
However, the normal heart may counter-regulate against 
‘excessive’ metabolism of ketone bodies in the presence 
of increased production [11].
Our hypothesis is that type 2 diabetic patients undergo-
ing coronary angiography/revascularization procedures for 
coronary heart disease (CHD) may show increased KB 
levels, depending on stress, diabetes control, and fasting 
duration.
Therefore, the objectives of this pilot study were (1) 
to determine the concentrations of capillary 3BOHB in 
patients with suspected CHD, with and without type 2 dia-
betes, undergoing elective coronary angiography, either 
with or without revascularization; (2) to establish the effect 
of fasting duration on 3BOHB concentrations; and (3) to 
detect 3BOHB modification during the procedure.
Subjects and methods
Subjects
In this prospective, cohort study, 16 type 2 diabetic patients 
(T2DM) and 22 matched controls admitted to Hospital, 
eligible for elective coronary angiography, were enrolled. 
Diabetes status was defined as (1) ongoing antidiabetic 
treatment; and (2) a HbA1c > .5% (48  mmol/mol). The 
decision for PTCA during coronary angiography was left 
to the discretion of interventional cardiologist. Recruit-
ment started on January 2013, and ended on September 
2015. Elective angiography was deemed necessary to rule 
out CHD, as for clinical indication. Patients with factors 
that could influence the lipid profile (alcohol abuse, thyroid 
disease, kidney, and liver disease) were excluded from the 
study. All patients received aspirin (100 mg daily) for the 
entire study period. Exclusion criteria were type 1 diabetes, 
active immunologic, neoplastic, and major organ diseases/
failure.
Patients were maintained on their usual therapy, and 
consumed a weight maintaining diet containing at least 200 
grams of carbohydrates per day for at least 2 days before 
the study. All patients enrolled in the study were on anti-
platelets agents, statin therapy, renin-angiotensin blockers.
Informed consent was obtained from each subject. The 
study protocol was approved by the local Institutional 
Review Board.
Study protocol
At hospital admission, in each patient, the following 
parameters were collected: sex, age, height, weight, BMI, 
arterial blood pressure, heart rate, family history of CHD 
and diabetes, the presence of cardiovascular disease (CVD) 
or arterial hypertension, smoke habit, and active therapy. 
A fasting blood sample for the determination of plasma 
glucose, glycated haemoglobin, creatinine, CKD-EPI esti-
mated glomerular filtration rate (eGFR), total cholesterol, 
HDL cholesterol, triglyceride, troponin I, and BNP was 
collected. LDL cholesterol was calculated by Friedwald 
formula; urine was collected for the determination of 
microalbuminuria.
Determinations of 3BOHB, glucose (StatStrip® 
XpressMeter Gluc/Ket—Nova Biomedical), and creati-
nine (StatSensor Xpress® CREAT—Nova Biomedical) 
were performed on venous blood, at 7 a.m, the morning 
of the coronary angiography, and then immediately before 
(3BOHB and glucose only) and after the procedure. The 
duration of the fasting period and of the procedure was 
recorded.
Elective coronary angiography was performed using 
the standard technique by percutaneous femoral or radial 
approach. All patients were pretreated with aspirin and 
clopidogrel. At the beginning of the procedure, a bolus of 
unfractionated heparin was administered in order to achieve 
an activated clotting time of >250 s; heparin was stopped 
at the end of the procedure in the absence of coexisting 
indications such as bedside treatment with an intra-aor-
tic balloon pump. Cardiac injury markers were routinely 
measured.
Analytical determinations
The determination of blood glucose, 3BHOB, and creati-
nine was performed with a point-of-care approach, apply-
ing a drop of venous blood to the StatStrip® XpressMeter 
Gluc/Ket and StatSensor Xpress® CREAT—Nova Bio-
medical, as per manufacturer’s instructions for immediate 
testing. The StatStrip® XpressMeter Gluc/Ket and StatSen-
sor Xpress® CREAT (http://www.novabiomedical.com/
products/statsensor-creatinine/) measurements were per-
formed in duplicate for glucose, 3BOHB, and creatinine. 
Testing methodological aspects are reported elsewhere [12, 
13]. In this study, we measured whole blood beta hydroxy-
butyrate levels as this is the principal and most abundant 
ketone body found in ketoacidosis [14] and has previously 
been shown to be a reliable indicator of altered mitochon-
drial redox state and ketone body production during fasting 
[7, 15–17]. The performance of whole blood tests including 
StatStrip Ketone has previously been validated against lab-
oratory methods in published studies [12, 18, 19]. In these 
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studies, StatStrip Ketone has demonstrated a good correla-
tion to the reference laboratory methods used and also to an 
GCMS definitive traceable method used for measuring for 
low levels of BOHB in metabolic conditions [20]. Based on 
these studies, it was considered that StatStrip Ketone was 
acceptable for use in the study without the need for further 
analytical evaluation.
Plasma glucose was determined by the glucose oxidase 
method; creatinine by the Jaffe method. Glycated haemo-
globin was determined with HPLC procedure; total cho-
lesterol, HDL cholesterol, and triglyceride were measured 
by enzymatic colorimetric test. BNP and troponin I were 
determined by immunoenzymatic methods. Microalbumi-
nuria was dosed by a turbidimetric method.
Statistical analysis
Study Size. A total of 38 patients (16 with diabetes and 22 
without diabetes) were recruited in this study, allowing a 
probability of 80% that the study detected a blood 3BOHB 
concentration difference at a two-sided 0.05 significance 
level, between diabetic and non-diabetic subjects, if the true 
difference between groups is 50  µmol/l. This is based on 
the assumption that the standard deviation of the response 
variable is 0.5. Data are expressed as mean ± standard devi-
ation. Normal distribution was verified with the Kolmog-
orov–Smirnov test. Differences between the two groups 
were assessed using the Student t test for unpaired data or 
Mann–Whitney test for non-normally distributed variables. 
Univariate correlations were checked using the Pearson’s 
r coefficient. Data are expressed as mean ± SD. Statistical 
significance was accepted at p < 0.05 and the SPSS ver-
sion 21.0 (IBM SPSS statistics for Windows, Version 21.0 
Armonk, NY, IBM Corp.) was used.
Results
Table 1 summarizes demographic, clinical, and biochemi-
cal parameters of the study subjects.
Table 1  Main demographic, 
clinical, and biochemical 
parameters of the study subjects
BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glo-
merular filtration rate, CHD coronary heart disease, CAG coronary angiography
a Heart failure was defined by a BNP value >300 pg/ml
b Either metformin, SUs, Glitazones
c Either dipeptidyl peptidase 4 inhibitors or glucagon like peptide-1 receptor agonist
Variable Type 2 diabetes (n = 16) Controls (n = 22) p
Age (years) 72 ± 11 71 ± 12 0.673
Female (%) 25 32 0.847
BMI (kg/m2) 28.0 ± 3.4 26.4 ± 2.9 0.124
Blood Pressure (systolic/diastolic) (mm Hg) 141 ± 16/79 ± 9 147 ± 17/82 ± 8 0.218/0.325
Heart rate (bpm) 83 ± 15 81 ± 14 0.790
History of hypertension (%) 94 77 0.049
Stable angina (%) 13 5 0.359
Heart  failurea (%) 33 27 0.692
Previous revascularization (%) 13 14 0.918
Troponin I (µg/l) 0.38 ± 0.86 0.11 ± 0.24 0.168
BNP (pg/ml) 534 ± 679 348 ± 552 0.367
Duration of diabetes (years) 12 ± 5 NA –
eGFR (ml/min/1.73 m2) (CKD-EPI) 69 ± 25 88 ± 33 0.063
Microalbuminuria (mg/24h) 123 ± 105 32 ± 46 0.004
HbA1c (%) (mmol/mol) 7.8 ± 3.9 (62 ± 20) 5.7 ± 0.2 (39 ± 2) 0.026
Total cholesterol (mg/dl) 163 ± 44 176 ± 44 0.370
HDL cholesterol (mg/dl) 42 ± 12 47 ± 9 0.087
LDL cholesterol (mg/dl) 107 ± 40 121 ± 40 0.296
Triglycerides (mg/dl) 138 ± 94 111 ± 37 0.288
Active Smoking (%) 19 45 0.0867
Insulin therapy (%) 27 – –
Oral antidiabetic  agentsb (%) 69 – –
Incretinsc (%) 27 – –
CHD demonstrated by CAG (n) (%) (87) (50) 0.0161
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Type 2 diabetic patients were comparable to controls in 
demographical indexes. However, they had significantly 
lower eGFR and significantly higher microalbuminuria 
excretion rate. No differences were observed in troponin I 
and BNP circulating levels.
As expected, diabetic patients had significantly higher 
fasting plasma glucose than controls.
The length of fasting to procedure was almost identical 
between the two groups (T2DM 849 ± 163 vs 787 ± 29 min; 
p = 0.085); however, the length of procedure was signifi-
cantly longer in diabetic patients (76 ± 36 min) than in con-
trols (46 ± 23 min; p = 0.007).
Figure  1 illustrates glucose and 3BOHB concentra-
tions, in the three different conditions (i.e. baseline, pre-, 
and post-procedure) in T2DM patients and in control sub-
jects. As indicated in Fig. 1b, diabetic patients had signif-
icantly higher fasting 3BOHB concentration than controls 
(0.538 ± 0.320 vs 0.255 ± 0.197  mM/l; p = 0.005). Also 
pre-procedural 3BOHB concentration was significantly 
higher in diabetic patients than controls (0.725 ± 0.429 vs 
0.314 ± 0.205 mM/l; p = 0.002). Post-procedural 3BOHB 
was also significantly higher in the former group, with an 
absolute increment of 3BOHB from the morning value of 
0.369 ± 0.252 (0.127 ± 0.135 nM/l in controls; p = 0.002). 
This increment is due to an enhanced ketone body 
production in diabetes, rather than to a reduced clear-
ance, as already demonstrated [21]. However, there was 
no correlation between 3BOHB increment and procedure 
duration.
After pooling the results of the two groups, signifi-
cant correlations were observed between pre-proce-
dural glucose and pre-procedural 3BOHB (r2 = 0.586; 
p < 0.0001) (Fig. 2a), and between fasting plasma glucose 
and post-procedural 3BOHB concentrations (r2 = 0.554; 
p < 0.0001). Significant correlations were also observed 
between fasting creatinine and pre-procedural 3BOHB 
levels (r2 = 0.364; p = 0.029) (Fig.  2b), between post-
procedural creatinine and post-procedural 3BOHB con-
centrations (r2 = 0.423; p = 0.010), and between pre-pro-
cedural 3BHOB concentration and creatinine increment 
during the procedure (r2 = 0.512; p = 0.001).
A positive correlation was observed between fasting 
duration and fasting plasma glucose levels (r2 = 0.392; 
p < 0.015). On the other hand, we were unable to dem-
onstrate an association between fasting duration and 
































Fig. 1  Plasma glucose (a) and 3BOHB (b) levels in controls and type 
2 diabetic patients (T2DM), in three different occasions: at baseline, 
immediately pre-procedure and immediately post-procedure. *All 
p < 0.001 vs controls
Fasng Crea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Fig. 2  Correlations between pre-procedure glucose and pre-proce-
dure 3BOHB (a), and between fasting creatinine and pre-procedure 
3BOHB (b). (White dots controls; black dots T2DM subjects)
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Coronary angiography (CAG) revealed a coronary 
heart disease (CHD) in 25 subjects (66% of the whole 
cohort), of which 16% had one vessel involvement, 16% 
two vessels, and 34% three vessels. Twelve patients 
(32%) underwent a PTCA, and 10 patients (26%) a 
CABG. Comparing T2DM and controls, the former 
showed a significantly higher prevalence of CHD (n 14; 
87% vs n 11; 50%; p = 0.0161) (Table 1) and of three-ves-
sel disease (56 vs 18%; p = 0.0146). We then compared 
metabolic parameters in patients with vs without CHD. 
Comparing subjects with vs without CHD, no differences 
were observed for sex, age, blood pressure values, gly-
cated haemoglobin, lipid profile, troponin, BNP, while 
eGFR (72 ± 26 vs 95 ± 34 ml/min/1.73 m2; p = 0.032) and 
microalbuminuria (88 ± 99 vs 37 ± 47 mg/24h; p = 0.038) 
were significantly different in CHD subjects. Analysing 
glucose, 3BOHB, and creatinine values before and after 
CAG, pre-procedure 3BOB, and creatinine were signifi-
cantly higher in patients with CHD, in the entire cohort 
(Table  2); post-procedure creatinine and its increase 
during the procedure were also higher in CHD subjects, 
while 3BOH increase and post-procedure values did not 
reach the statistical significance, although more elevated 
in the CHD group (Table  2). No significant variations 
were observed for glucose values. Fasting and proce-
dure duration was similar in CHD and non-CHD patients 
(Table 2).
Discussion
The main findings of this study are that (1) blood 3BOHB 
concentrations are significantly higher in T2DM patients 
than in controls; (2) 3BOHB levels increase more sharply 
in the former group during a stress condition, such as an 
invasive diagnostic procedure, i.e. coronary angiography 
planned to either confirm or exclude CHD. The higher 
3BOHB concentration was observed despite a comparable 
fasting period before the angiographic procedure. Even 
higher concentrations were observed after the proce-
dure, although the length of this was significantly higher 
in diabetic patients. These results, obtained in a relatively 
small cohort of subjects, further stress the robustness of 
the observation, highlighting the metabolic role of these 
substrates also in T2DM, and the need of their determina-
tion, in a simple and fast manner, such as a point-of-care 
approach, in particular settings, to guarantee an optimal 
clinical management of diabetes.
We used the point-of-care determination of 3BOHB, 
which has been shown to be equally sensitive in detect-
ing diabetic ketoacidosis in humans [22–24]; the capillary 
3BOHB determination is easy and rapid to perform and 
gives objective results, which may improve management of 
the diabetic patient, especially in upsetting conditions [25]. 
Thus, the point-of-care capillary 3BOHB determination 
may be useful before any procedural/surgical intervention 
in T2DM patients.
Our data not only indicate that patients with type 2 dia-
betes may show increased KB concentration, but expand 
the findings of Lommi and colleagues, who showed that 
CHF had elevated blood KB (median 267  µmol/l) com-
pared with control subjects (median 150  µmol/l) [7]. We 
were unable to find any correlation between BNP, which 
identified patients with cardiac-related dyspnoea with 
a sensitivity of 99% and a specificity of 41% [26], and 
3BOHB concentration; however, our findings support an 
increased circulating 3BOHB concentration in T2DM 
patients independently of the presence of overt heart fail-
ure [15]. Notably, pooling T2DM and non-diabetic sub-
jects, those with CHD, documented at CAG, showed higher 
basal levels of both 3BOB and creatinine, but not of glu-
cose: to corroborate this finding, a significant correlation 
was observed between fasting troponin and 3BOHB values 
(r2 0.454; p = 0.005). Increased levels of 3BOHB have been 
described in both patients with and without diabetes with 
ischemic heart disease [27], as well as heart failure: it is 
Table 2  Comparisons of 
metabolic parameters between 
subjects with CHD vs without 
CHD, as documented by 
coronary angiography
Parameter Without CHD (n 25) With CHD (n 13) p
Pre-procedure glucose (mg/dl) 102 ± 26 115 ± 29 0.191
Post-procedure glucose (mg/dl) 100 ± 21 121 ± 38 0.076
Pre-procedure 3BOHB (mM/l) 0.35 ± 0.21 0.56 ± 0.42 0.044
Post-procedure 3BOHB (mM/l) 0.46 ± 0.25 0.68 ± 0.51 0.088
Pre-procedure creatinine (mg/dl) 0.85 ± 0.14 1.02 ± 0.26 0.015
Post-procedure creatinine (mg/dl) 1.00 ± 0.25 1.30 ± 0.33 0.009
Δglucose (mg/dl) −2 ± 19 6 ± 11 0.105
Δ3BOHB (mM/l) 0.16 ± 0.20 0.26 ± 0.23 0.187
Δcreatinine (mg/dl) 0.15 ± 0.17 0.28 ± 0.18 0.050
Fasting duration (min) 816 ± 117 812 ± 110 0.918
Procedure duration (min) 47 ± 27 64 ± 34 0.127
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well known that ketone bodies represent an alternative fuel 
source in the failing heart.
The present data also support our previous findings 
showing that blood levels of ketones are increased in 
T2DM patients, in spite of higher plasma insulin and no dif-
ferences in plasma levels of cortisol, and growth hormone 
[28]. Fasting and stressful conditions further stimulate KB 
metabolism in diabetic patients, and excessive ketogenesis 
can lead to critical ketoacidosis; therefore, the availabil-
ity of a simple point-of-care KB determination in peculiar 
clinical conditions is advised to monitoring the metabolic 
status of the patient. The analytical approach used herein 
detects only 3BOHB and not acetoacetate: however, in con-
ditions where KB are increased, there is a progressive shift 
of acetoacetate to 3BOHB so that the latter ketone is by far 
the most representative [29].
As shown in Fig. 2a, we show a direct, linear correlation 
between pre-procedural 3BOHB concentration and plasma 
glucose: this finding has important clinical implications 
since it underscores the need of a strict glycaemic control 
when a diagnostic procedure such as coronary angiogra-
phy is planned in patients with diabetes. In this context, 
KB were found to be increased during general anaesthesia 
without surgical stress as a consequence of prolonged fast-
ing [30]. More recently, increased KB concentrations were 
observed in children younger than 36 months, who can 
present with ketoacidosis and (low) normal blood glucose 
concentrations before surgical intervention: these authors 
emphasize, at least in this group of patients, a better opti-
mization of fasting time, in accordance with current guide-
lines [31].
Another finding, which deserves attention, is the direct 
correlation between creatinine levels and 3BHOB concen-
tration both in fasting condition (Fig. 2b), and post-proce-
dure, and also between 3BHOB concentration and creati-
nine increment during the procedure. Regrettably, there is 
no available report explaining the effect of chronic kidney 
disease on KB levels, and further studies are needed to 
corroborate this observation. On the contrary, it has been 
found that an acute increase in blood concentration of KB 
increases glomerular filtration rate in both control and in 
patients with diabetes patients, but it may cause a tubular 
proteinuria [32]. Recently, it was found that enhanced KB 
production in the diabetic kidney may represent a mecha-
nism involved in the pathogenesis of diabetic nephropathy 
[33].
The increased blood 3BOHB concentrations in our 
patients with diabetes may be determined by increased 
adrenergic activation secondary either to the stressful 
condition, and/or to the fasting condition. Beside the 
well-known effect of catecholamines on lipolysis, and the 
secondary rise in KB production, it has been shown that 
stressor situations may increase KB by more than 400% 
[34]: this increase, observed in normal weight subjects, 
was associated with a surge in ACTH, norepinephrine 
and epinephrine concentrations, which unfortunately we 
were unable to assess. Also fasting is a well-known con-
dition characterized by a progressive increase in circulat-
ing KB concentration [35]; the co-existence of both stress 
and prolonged fasting, probably in combination with the 
state of insulin resistance of T2DM patients, leads to 
higher 3BOHB levels in this group of subjects.
This study, albeit small, has however important clinical 
implications, the first being that the fasting state before an 
invasive and stressful procedure is characterized by an inap-
propriate elevation of circulating KB level. Although well 
below a life-threatening threshold, this increase in 3BOHB 
should be considered since, if not recognized properly, it 
may predispose to a more serious increase in its concen-
tration [36]. These results also should suggest reducing the 
length of the fasting period before any procedural or surgi-
cal intervention in hospitalized T2DM patients; addition-
ally, a diet richer in carbohydrates should be implemented 
in these patients, especially in those with SGLT2 inhibi-
tors, which can potentially increase 3BOHB reabsorption 
[5]. Notably, it has been recently hypothesized that in mild, 
persistent hyperketonemia, such as those that prevail during 
treatment with SGLT2 inhibitors, 3BOHB is freely taken 
up by the heart and oxidized in preference to fatty acids, 
being, this, a positive fuel selection to improve the trans-
duction of oxygen consumption into work efficiency at the 
mitochondrial level [37]. However, this theory has been 
criticized on biochemical ground [38]. It must be acknowl-
edged that one of the limitation of this study is that only 
3BOHB was determined, and this may not reflect the whole 
concentration of KB; additionally, the pre-procedural fast-
ing duration could not be sufficient long to determine a sig-
nificant increase of 3BOHB concentration.
In conclusion, a point-of-care and easy detection of 
3BOHB may represent an additional and relatively simple 
assay, which may assist the physician to avoid metabolic 
decompensation in hospitalized T2DM patients before 
and after invasive and stressful procedures.
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